Purigen Biosystems
Latest round
- Series B
Last raised
- Mar 2019
Total raised
- $55M
Investors
- 6
About Purigen Biosystems
Founded in 2012 and headquartered in Pleasanton, US, Purigen Biosystems focuses on simplifying genetic analysis. The company was acquired by BioNano Genomics, Inc. in November 2022 for USD 64 mn. Co-founders Juan Santiago and Klint Rose, along with CEO Barney Saunders, have extensive backgrounds in biotechnology, but specific prior ventures are not mentioned.Purigen Biosystems specializes in advanced genetic analysis solutions, primarily focused on its flagship product, the Ionic™ system. This innovative platform enables rapid and efficient extraction of high-quality nucleic acids from a variety of sample types, including whole blood, saliva, and tissue. The Ionic™ system is designed to enhance workflows in molecular diagnostics, research, and clinical labs by streamlining the preparation process and significantly reducing time-to-result. Purigen's solutions target a diverse clientele that includes clinical laboratories, research institutions, and biotechnology companies operating globally, with a notable presence in North America and Europe.Purigen Biosystems generates revenue through a combination of direct sales and partnerships with research institutions and clinical laboratories. The company's business model revolves around the sale of its Ionic™ system and associated consumables, which may be structured as one-time purchases or recurring orders based on laboratory needs. Customers typically engage in transactions involving the upfront acquisition of the system, followed by ongoing procurement of proprietary reagents and kits necessary for the extraction and analysis processes. Pricing plans for these products reflect their innovative technology and the value they add to genomic workflows, ensuring competitive positioning in the market.Following the acquisition by BioNano Genomics, Inc. in November 2022, Purigen Biosystems aims to advance its product offerings, particularly in simplifying DNA isolation for Optical Genome Mapping (OGM). The company plans to enhance its existing Ionic™ platform for new applications utilizing Isotachophoresis (ITP), targeting research and clinical markets in North America and Europe.
Who invested in Purigen Biosystems
6 investors across 3 rounds
See all investors in Purigen Biosystems
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Purigen Biosystems
Who invested in Purigen Biosystems?
Purigen Biosystems has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Purigen Biosystems raised?
Purigen Biosystems has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Purigen Biosystems last raise money?
Purigen Biosystems's most recent round on record is a Series B, in Mar 2019.
What does Purigen Biosystems do?
Founded in 2012 and headquartered in Pleasanton, US, Purigen Biosystems focuses on simplifying genetic analysis.
Where is Purigen Biosystems headquartered?
Purigen Biosystems is headquartered in Pleasanton, US.
Which VCs invest in companies like Purigen Biosystems?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Purigen Biosystems's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Purigen Biosystems? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.